Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market Expected To Change From 2026 To 2030?
The isocitrate dehydrogenase (idh) inhibitors market has seen substantial growth in recent years. It is anticipated to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. Historically, this growth can be ascribed to advancements in cancer genomics research, the pressing unmet needs in oncology, the rise of mutation-driven drug discovery, increasing hospital oncology adoption, and the expansion of clinical trials.
The isocitrate dehydrogenase (idh) inhibitors market is poised for significant expansion in the coming years. It is projected to achieve a value of $8.02 billion by 2030, growing at a compound annual growth rate (CAGR) of 26.6%. This anticipated growth is driven by advancements in precision medicine, biomarker-driven oncology care, the development of drugs for rare cancers, the adoption of combination cancer therapies, and regulatory support for targeted medications. Key trends expected during this forecast period include the broader application of targeted oncology treatments, an increase in drug development based on genetic mutations, a heightened focus on rare cancer therapies, the rising utilization of precision oncology diagnostics, and ongoing progress in small molecule cancer inhibitors.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24577&type=smp
What Factors Are Contributing To The Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
The rising occurrence of acute myeloid leukemia (AML) is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market in the future. AML is a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that hinder typical blood cell formation. The heightened incidence of AML stems from an increase in the elderly population, as older individuals are at a greater risk of developing this severe blood cancer due to age-related alterations in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors are effective in treating acute myeloid leukemia by inhibiting mutant IDH enzymes, thereby facilitating the restoration of normal blood cell development and slowing the proliferation of leukemia cells. For example, a report released in February 2023 by the Leukaemia Foundation, an Australia-based non-profit organization, projects that between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to receive a diagnosis of blood cancers, mainly acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is expected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
Which Segments Define The Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Structure?
The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
What Trends Are Affecting The Growth Of The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Leading companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing the attainment of regulatory approvals to expand the clinical utility of their therapies, expedite market entry, and secure a competitive advantage in addressing IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities that permit a drug’s marketing and use after confirming its safety and effectiveness. A notable instance occurred in August 2024, when Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets. This marked its recognition as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, encompassing astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment demonstrated a significant improvement in progression-free survival, as observed in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months compared to 11.1 months for those on placebo. VORANIGO offers a convenient and well-tolerated option with manageable side effects, representing a substantial advancement for a patient group that previously faced limited treatment choices.
Who Are The Established Players Within The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
Get The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:
Which Region Is The Leading Market For The Isocitrate Dehydrogenase (IDH) Inhibitors Market?
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Isocitrate Dehydrogenase (IDH) Inhibitors Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Isocitrate Dehydrogenase (IDH) Inhibitors Market 2026, By The Business Research Company
Histone Deacetylase Inhibitors Market Report 2026
Metabolic Disorders Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Proton Pump Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/proton-pump-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
